Preclinical studies have shown that certain drugs, such as AZD0530 (which has an affinity for the ATP binding site in Src) and vandetanib (vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and RET tyrosine kinases inhibitor) have important effects in reversing the invasive phenotype of breast cancer cells. This evidence concerns the gene SRC and breast cancer.